Drugs / AGN-229666
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01754766 | Oct 2012 → Jan 2013 | eye allergy | Allergan | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02161146 | Jun → Dec 2014 | conjunctivitis | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT02082262 | Mar → Jul 2014 | conjunctivitis | Allergan | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGN-229666 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02161146 ↗ |
| Route | Topical | “One drop of AGN-229666 into each eye on Day 1 and Day 15.” NCT01754766 ↗ |